Korea Exchange · Healthcare
Shinpoong Pharmaceutical stock from India: price, numbers and tax
Shinpoong Pharmaceutical (019170) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Shinpoong Pharmaceutical at a glance
- Price
- ₩9,780.00-₩1,230.00 (11.17%)
- Market cap
- ₩505.71B
- Day range
- ₩9,750.00 – ₩10,130.00
- P/E
- -1024.08
- Dividend yield
- None
- Volume
- 867.15K
- 1 month
- -0.41%
- 6 months
- -5.51%
- YTD
- -30.34%
- 1 year
- -26.36%
- 5 years
- -83.94%
Shinpoong Pharmaceutical statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | ₩234.7B | ₩221.1B | ₩200.2B | ₩209.3B | ₩189.2B |
| Gross profit | ₩102.4B | ₩81.8B | ₩80.3B | ₩78.0B | ₩77.4B |
| Operating income | ₩14.3B | −₩20.5B | −₩47.4B | −₩34.0B | −₩9.0B |
| Net income | ₩8.8B | −₩15.4B | −₩57.3B | −₩35.3B | −₩11.5B |
| Earnings per share | ₩172.00 | −₩300.17 | −₩1,119.00 | −₩688.79 | −₩224.84 |
| EBITDA | ₩25.6B | −₩27.1M | −₩39.8B | −₩21.9B | ₩3.9B |
| Total assets | ₩352.5B | ₩342.1B | ₩350.1B | ₩361.5B | ₩392.6B |
| Total debt | ₩55.9B | ₩54.6B | ₩46.2B | ₩1.9B | ₩1.2B |
| Cash and short-term investments | ₩71.5B | ₩56.5B | ₩60.5B | ₩55.9B | ₩92.7B |
| Shareholders' equity | ₩270.0B | ₩256.8B | ₩269.6B | ₩329.6B | ₩353.5B |
| Operating cash flow | ₩17.3B | −₩15.2B | −₩24.8B | −₩26.4B | −₩71.0B |
| Free cash flow | ₩13.8B | −₩21.2B | −₩39.9B | −₩32.7B | −₩76.6B |
| Capital expenditure | −₩3.5B | −₩6.1B | −₩15.0B | −₩6.2B | −₩5.6B |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in KRW; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Daewoong pharmaceutical | 069620.KS | ₩108,500.00 | ₩1.25T |
| Ildong Pharmaceutical | 249420.KS | ₩14,020.00 | ₩441.74B |
| Bukwang Pharmaceutical | 003000.KS | ₩4,055.00 | ₩400.09B |
| Yungjin Pharm. | 003520.KS | ₩1,035.00 | ₩189.29B |
| Hyundai Pharmaceutical | 004310.KS | ₩7,760.00 | ₩181.97B |
| Daewon Pharmaceutical | 003220.KS | ₩8,190.00 | ₩175.54B |
| Daihan Pharmaceutical | 023910.KQ | ₩25,850.00 | ₩152.00B |
| Dongwha Pharm | 000020.KS | ₩5,360.00 | ₩148.57B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Shinpoong Pharmaceutical from India
What Shinpoong Pharmaceutical does
Shinpoong Pharmaceutical Co., Ltd. is a South Korean company that manufactures and distributes a broad spectrum of pharmaceutical products. Its portfolio includes both cephalosporin and penicillin antibiotics, alongside other finished medications. Shinpoong Pharmaceutical operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Shinpoong Pharmaceutical shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the KRW/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.